Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

ASPARAGINASE for Neoplasm malignant: Side Effects & Safety Data

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

There are 12 adverse event reports in the FDA FAERS database where ASPARAGINASE was used for Neoplasm malignant.

Most Reported Side Effects for ASPARAGINASE

Side Effect Reports % Deaths Hosp.
Febrile neutropenia 557 11.2% 96 270
Neutropenia 322 6.5% 50 130
Bacterial infection 295 5.9% 255 10
Off label use 267 5.4% 118 88
Secondary immunodeficiency 233 4.7% 212 3
Viral infection 228 4.6% 228 3
Clostridium difficile colitis 213 4.3% 201 16
Pyrexia 204 4.1% 39 123
Sepsis 200 4.0% 95 70
Pneumonia 196 3.9% 143 41
Posterior reversible encephalopathy syndrome 195 3.9% 4 63
Bronchopulmonary aspergillosis 194 3.9% 163 11
Drug ineffective 192 3.9% 72 59
Mycobacterium chelonae infection 170 3.4% 170 1
Death 169 3.4% 169 10

Other Indications for ASPARAGINASE

Acute lymphocytic leukaemia (2,690) T-cell type acute leukaemia (282) Product used for unknown indication (278) B precursor type acute leukaemia (214) B-cell type acute leukaemia (207) Angiocentric lymphoma (148) Non-hodgkin's lymphoma (135) Precursor t-lymphoblastic lymphoma/leukaemia (118) Chemotherapy (98) Acute myeloid leukaemia (68)

Other Drugs Used for Neoplasm malignant

PALBOCICLIB (1,996) CAPECITABINE (1,493) PEMBROLIZUMAB (1,135) PACLITAXEL (984) CARBOPLATIN (977) NIVOLUMAB (947) OXALIPLATIN (823) PAZOPANIB (716) CYCLOPHOSPHAMIDE (685) FLUOROURACIL (676)

Related Pages

ASPARAGINASE Full Profile All Neoplasm malignant Drugs ASPARAGINASE Demographics ASPARAGINASE Timeline